Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-54

Azercel Time line advised to the market 18/08/2023
It would appear they are running at least 3 months behind their initial guidance, it not a little more. This would then push their phase 1b read out to Q4 2024

For balance 2H 2024 - can mean 1st of June 2024 - so maybe they will surprise us with some new data in June, though I wont be holding my breath.

As to the MAST trial - The company is on record stating they will only cut data for a major conference presentations, and wont be doing regular data cuts due to cost and it slows down their trial progress. I am not aware of any upcoming major cancer conferences where IMU is booked to present.

2024 is defining into a make or break year for IMU (And for me personally if I continue to hold).
They will defiantly look to release some major news to us in the coming 6 - 8 months, with a capital raise after the re rate (and if the news is solid and substantial I'll be happy to participate and give them my support if Retail Holders are asked to participate).

After the Hervaxx experience I've learnt to be wary when everything is projected as "positive" but there is an information vacuum.
This company has 4 clinical trials underway (reduced from 5 with the early withdrawn of Hervaxx in March 2024) and its little to say apart from "watch this space" and "we are eager to update you soon".

Dare I even ask the company what is going on with "Checkvacc"? (Likely I'll just get fobbed off).
Triple Negative Breast Cancer - High impact unmet need. The first trial to us CF33 / Vaxinia virus in humans. They started in October 2021. I remember one positive announcement with observed pseudo progression. Then crickets... Trial is due to complete in September 2024
Maybe that will be our Christmas present...